Click to cell type (#count): Oligodendrocyte (5230) Macrophage (3328) Astrocyte (684) Smooth muscle cell (169)
Tissue and cell type-associated traits map for all cell types in [AdultTemporalLobe] [link to TSEA] . Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-05 as default, and users can change it to 1e-04, 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple trait-associated-gene (TAG) sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below. Users could further select to only show the association for those ‘tissue-specfic cell types’ defined from ontology analysis.
Table. List of Tissue-cell type associated traits pairs for [AdultTemporalLobe]. If the network above is too complicated, the users could obtain the association information from the table at bottom. Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Cell type | Trait name | Trait full name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|---|
Oligodendrocyte | ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 5.00e-2 | 2.29e-2 |
Astrocyte | Age At Death | Age At Death | MTC | Pilling | 2016 | NA | 45627 | 1.00e-2 | 2.29e-2 |
Oligodendrocyte | Age At Menarche | Age At Menarche | ETC | Perry | 2014 | NA | 182413 | 1.00e-5 | 4.64e-2 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 5.00e-2 | 8.83e-6 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-2 | 5.07e-6 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-3 | 2.75e-6 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-4 | 1.73e-7 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-5 | 2.69e-6 |
Macrophage | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 5.00e-2 | 1.28e-3 |
Macrophage | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-2 | 6.46e-3 |
Macrophage | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-3 | 3.22e-3 |
Macrophage | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-4 | 2.75e-3 |
Macrophage | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-5 | 3.08e-3 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 5.00e-2 | 4.54e-3 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-2 | 6.19e-4 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-3 | 2.04e-3 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-4 | 9.52e-4 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-5 | 8.16e-4 |
Smooth muscle cell | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-4 | 2.15e-2 |
Smooth muscle cell | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-5 | 3.19e-2 |
Macrophage | Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | MTC | van-Rheenen | 2016 | 12577 | 23475 | 1.00e-2 | 2.10e-2 |
Macrophage | Anorexia Nervosa | Anorexia Nervosa | MTC | Duncan | 2017 | 3495 | 10982 | 1.00e-2 | 1.62e-2 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 5.00e-2 | 4.94e-2 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-2 | 2.36e-3 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-3 | 9.71e-6 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-4 | 1.16e-6 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-5 | 7.86e-5 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 5.00e-2 | 6.87e-3 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-2 | 8.97e-3 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-3 | 3.31e-2 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-4 | 4.08e-2 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-5 | 4.36e-2 |
Oligodendrocyte | Birth Weight | Birth Weight | MTC | Horikoshi | 2013 | NA | 26836 | 5.00e-2 | 5.17e-3 |
Smooth muscle cell | Birth Weight | Birth Weight | MTC | Horikoshi | 2013 | NA | 26836 | 5.00e-2 | 3.36e-3 |
Macrophage | Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 1.00e-4 | 4.91e-2 |
Oligodendrocyte | BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 5.00e-2 | 6.35e-3 |
Oligodendrocyte | BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-2 | 8.10e-3 |
Oligodendrocyte | BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-3 | 1.23e-2 |
Oligodendrocyte | BMI | Body Mass Index | MTC | Speliotes | 2010 | NA | 123865 | 5.00e-2 | 1.60e-2 |
Oligodendrocyte | BMI | Body Mass Index | MTC | Speliotes | 2010 | NA | 123865 | 1.00e-3 | 7.23e-3 |
Oligodendrocyte | BMI | Body Mass Index | MTC | Speliotes | 2010 | NA | 123865 | 1.00e-5 | 3.71e-2 |
Smooth muscle cell | BMI | Body Mass Index | MTC | Speliotes | 2010 | NA | 123865 | 1.00e-4 | 3.71e-2 |
Macrophage | Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 1.21e-2 |
Macrophage | Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 1.00e-2 | 2.87e-3 |
Astrocyte | Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 4.19e-2 |
Oligodendrocyte | Cerebral White Matter Hyperintensity | Cerebral White Matter Hyperintensity | MTC | Traylor | 2016 | NA | 3670 | 5.00e-2 | 3.75e-2 |
Macrophage | Clozapine Induced Agranulocytosis | Clozapine Induced Agranulocytosis | ETC | Goldstein | 2014 | 161 | 1196 | 5.00e-2 | 5.24e-3 |
Oligodendrocyte | Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 5.00e-2 | 3.60e-2 |
Oligodendrocyte | Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 1.00e-2 | 9.54e-3 |
Macrophage | Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 5.00e-2 | 1.16e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-2 | 4.79e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-3 | 4.20e-2 |
Macrophage | CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-3 | 4.20e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-2 | 3.63e-3 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-3 | 4.46e-2 |
Macrophage | CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-3 | 2.32e-2 |
Oligodendrocyte | CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-5 | 2.57e-2 |
Macrophage | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 5.00e-2 | 4.59e-5 |
Macrophage | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-2 | 1.07e-5 |
Macrophage | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-3 | 1.00e-2 |
Macrophage | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-4 | 1.74e-4 |
Macrophage | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-5 | 1.91e-4 |
Macrophage | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 5.00e-2 | 1.37e-3 |
Macrophage | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-2 | 2.80e-2 |
Macrophage | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-3 | 1.12e-2 |
Macrophage | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-4 | 3.21e-3 |
Macrophage | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 5.00e-2 | 2.51e-3 |
Macrophage | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-2 | 6.74e-4 |
Macrophage | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-3 | 7.19e-3 |
Macrophage | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-4 | 3.64e-4 |
Macrophage | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-5 | 1.50e-3 |
Smooth muscle cell | Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 4.23e-2 |
Smooth muscle cell | Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 1.61e-3 |
Smooth muscle cell | Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 2.29e-2 |
Astrocyte | Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 1.61e-3 |
Smooth muscle cell | Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 5.00e-2 | 4.23e-2 |
Smooth muscle cell | Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-2 | 1.61e-3 |
Smooth muscle cell | Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-3 | 2.29e-2 |
Astrocyte | Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-2 | 1.61e-3 |
Macrophage | Head Circumference | Head Circumference | MTC | Taal | 2012 | NA | 10768 | 5.00e-2 | 1.84e-3 |
Macrophage | Head Circumference | Head Circumference | MTC | Taal | 2012 | NA | 10768 | 1.00e-2 | 3.06e-3 |
Oligodendrocyte | Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 5.00e-2 | 6.43e-3 |
Oligodendrocyte | Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-2 | 4.85e-2 |
Oligodendrocyte | Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-3 | 4.80e-2 |
Macrophage | Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-4 | 9.53e-3 |
Macrophage | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 5.00e-2 | 1.72e-3 |
Macrophage | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-2 | 4.47e-3 |
Macrophage | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-3 | 3.05e-3 |
Oligodendrocyte | Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 5.00e-2 | 2.60e-2 |
Oligodendrocyte | Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 1.00e-3 | 1.29e-3 |
Oligodendrocyte | Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 1.00e-4 | 1.21e-2 |
Astrocyte | MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 5.00e-2 | 3.07e-2 |
Macrophage | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 5.00e-2 | 1.31e-5 |
Macrophage | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-2 | 9.88e-5 |
Macrophage | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-3 | 2.80e-8 |
Macrophage | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-4 | 2.07e-10 |
Macrophage | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-5 | 4.48e-10 |
Macrophage | Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 7.65e-3 |
Oligodendrocyte | Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 5.00e-2 | 5.85e-3 |
Oligodendrocyte | Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-2 | 2.22e-2 |
Oligodendrocyte | Obesity Childhood | Obesity Childhood | MTC | Bradfield | 2012 | 5530 | 8318 | 5.00e-2 | 2.09e-2 |
Macrophage | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-2 | 5.23e-3 |
Macrophage | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-3 | 6.58e-3 |
Macrophage | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-4 | 1.22e-2 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 1.15e-4 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-2 | 1.26e-7 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-3 | 1.95e-9 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-4 | 8.07e-10 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-5 | 1.56e-10 |
Macrophage | Prostate Cancer | Prostate Cancer | MTC | Yeager | 2007 | 1172 | 1157 | 5.00e-2 | 2.82e-2 |
Smooth muscle cell | Prostate Cancer | Prostate Cancer | MTC | Yeager | 2007 | 1172 | 1157 | 1.00e-2 | 4.61e-2 |
Macrophage | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-2 | 3.33e-3 |
Macrophage | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-3 | 6.78e-3 |
Macrophage | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-4 | 3.96e-3 |
Macrophage | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-5 | 2.51e-3 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 5.00e-2 | 4.14e-4 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-2 | 1.45e-6 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-3 | 4.18e-11 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-4 | 7.44e-13 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-5 | 2.22e-13 |
Macrophage | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-2 | 1.31e-2 |
Macrophage | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-3 | 1.69e-2 |
Macrophage | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-4 | 1.97e-2 |
Macrophage | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-5 | 8.63e-3 |
Macrophage | Sleep Duration | Sleep Duration | MTC | Marinelli | 2016 | NA | 10554 | 1.00e-3 | 4.90e-2 |
Oligodendrocyte | Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 1.13e-2 |
Oligodendrocyte | Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 1.00e-2 | 4.13e-2 |
Macrophage | Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 1.00e-4 | 4.08e-2 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 5.00e-2 | 1.27e-4 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-2 | 2.79e-4 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-3 | 2.33e-5 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-4 | 4.10e-8 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-5 | 2.86e-7 |
Macrophage | Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 5.00e-2 | 1.91e-2 |
Macrophage | Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 1.00e-2 | 1.83e-2 |
Macrophage | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-4 | 2.61e-2 |
Macrophage | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-5 | 2.55e-3 |
Oligodendrocyte | Warfarin maintenance dose | Warfarin maintenance dose | MTC | Cooper | 2008 | NA | 181 | 5.00e-2 | 1.26e-2 |
Oligodendrocyte | Warfarin maintenance dose | Warfarin maintenance dose | MTC | Cooper | 2008 | NA | 181 | 1.00e-2 | 9.68e-3 |
Macrophage | Warfarin maintenance dose | Warfarin maintenance dose | MTC | Cooper | 2008 | NA | 181 | 5.00e-2 | 4.56e-2 |
Smooth muscle cell | Albuminuria | Microalbuminuria | MTC | Boger | 2011 | NA | 31580 | 5.00e-2 | 2.41e-2 |
Smooth muscle cell | Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 5.00e-2 | 1.62e-3 |
Smooth muscle cell | Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 1.00e-3 | 7.11e-3 |
Astrocyte | Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 1.00e-3 | 7.11e-3 |
Smooth muscle cell | Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 5.00e-2 | 3.60e-2 |
Astrocyte | Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 1.00e-2 | 1.95e-2 |
Macrophage | Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 5.00e-2 | 4.14e-3 |
Oligodendrocyte | Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 1.00e-2 | 2.69e-3 |
Smooth muscle cell | Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 5.00e-2 | 2.03e-2 |
Smooth muscle cell | Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 1.00e-2 | 2.55e-2 |
Smooth muscle cell | Alcohol Consumption | Alcohol Consumption All Continuous | MTC | Schumann | 2016 | NA | 70460 | 1.00e-3 | 3.19e-2 |
Smooth muscle cell | Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 5.00e-2 | 4.17e-2 |
Oligodendrocyte | Alcohol Consumption | Alcohol Consumption Men Continuous | MTC | Schumann | 2016 | NA | 27560 | 5.00e-2 | 4.38e-2 |
Oligodendrocyte | Alcohol Consumption | Alcohol Consumption Men Continuous | MTC | Schumann | 2016 | NA | 27560 | 1.00e-2 | 7.85e-3 |
Astrocyte | Alcohol Consumption | Alcohol Consumption Men Continuous | MTC | Schumann | 2016 | NA | 27560 | 5.00e-2 | 3.71e-3 |
Macrophage | Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 5.00e-2 | 3.96e-2 |
Astrocyte | Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 4.65e-2 |
Oligodendrocyte | Anthropometric Extremes | Extreme BMI | MTC | Berndt | 2013 | 7962 | 8106 | 5.00e-2 | 2.14e-2 |
Oligodendrocyte | Anthropometric Extremes | Extreme BMI | MTC | Berndt | 2013 | 7962 | 8106 | 1.00e-2 | 2.60e-2 |
Oligodendrocyte | Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 5.00e-2 | 3.26e-2 |
Oligodendrocyte | Anthropometric Extremes | Obesity Class 2 | MTC | Berndt | 2013 | 9889 | 65840 | 1.00e-2 | 1.24e-2 |
Oligodendrocyte | Anthropometric Extremes | Obesity Class 3 | MTC | Berndt | 2013 | 2896 | 65840 | 1.00e-2 | 2.70e-2 |
Oligodendrocyte | Anthropometrics Sex Stratified | Body Mass Index Men | MTC | Randall | 2013 | 60586 | 60856 | 1.00e-4 | 1.93e-2 |
Oligodendrocyte | Anthropometrics Sex Stratified | Body Mass Index Women | MTC | Randall | 2013 | NA | 73137 | 5.00e-2 | 1.31e-2 |
Oligodendrocyte | Anthropometrics Sex Stratified | Body Mass Index Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-2 | 8.78e-3 |
Astrocyte | Anthropometrics Sex Stratified | Body Mass Index Women | MTC | Randall | 2013 | NA | 73137 | 5.00e-2 | 1.37e-3 |
Oligodendrocyte | Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-4 | 1.79e-2 |
Astrocyte | Anthropometrics Sex Stratified | Hip Circumference Men | MTC | Randall | 2013 | NA | 34942 | 1.00e-3 | 3.71e-2 |
Oligodendrocyte | Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 5.00e-2 | 4.51e-2 |
Smooth muscle cell | Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-2 | 1.93e-2 |
Oligodendrocyte | Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 5.00e-2 | 4.97e-2 |
Oligodendrocyte | Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-2 | 2.49e-3 |
Oligodendrocyte | Anthropometrics Sex Stratified | Waist Circumference Women | MTC | Randall | 2013 | NA | 45192 | 5.00e-2 | 3.92e-2 |
Oligodendrocyte | Anthropometrics Sex Stratified | Waist Circumference Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-2 | 2.16e-2 |
Oligodendrocyte | Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 5.00e-2 | 1.29e-2 |
Oligodendrocyte | Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-3 | 7.17e-3 |
Oligodendrocyte | Anthropometrics Sex Stratified | Waist Hip Ratio Women | MTC | Randall | 2013 | NA | 42969 | 5.00e-2 | 3.45e-2 |
Oligodendrocyte | Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-2 | 2.34e-2 |
Oligodendrocyte | Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-3 | 8.80e-3 |
Macrophage | Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-2 | 3.69e-2 |
Macrophage | Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-3 | 3.64e-2 |
Macrophage | Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-4 | 2.68e-2 |
Smooth muscle cell | Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 1.00e-2 | 5.27e-3 |
Oligodendrocyte | Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 1.00e-3 | 2.21e-2 |
Smooth muscle cell | Anxiety | Anxiety Dichotomous | MTC | Otowa | 2016 | 7016 | 14745 | 5.00e-2 | 3.15e-3 |
Astrocyte | Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 1.00e-2 | 5.98e-3 |
Astrocyte | Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 5.00e-2 | 1.60e-2 |
Astrocyte | Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 1.00e-2 | 5.73e-3 |
Smooth muscle cell | Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 1.00e-2 | 3.86e-2 |
Oligodendrocyte | Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 5.00e-2 | 1.54e-2 |
Oligodendrocyte | Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-2 | 4.90e-2 |
Macrophage | Blood Cells | Basophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.34e-2 |
Macrophage | Blood Cells | Eosinophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.85e-2 |
Macrophage | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 8.29e-3 |
Macrophage | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.45e-4 |
Macrophage | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 3.74e-5 |
Macrophage | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-4 | 1.54e-4 |
Macrophage | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-5 | 3.99e-3 |
Macrophage | Blood Cells | Mean Corpuscular Hemoglobin Concentration | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.50e-3 |
Oligodendrocyte | Blood Cells | Monocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 6.39e-3 |
Macrophage | Blood Cells | Monocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.38e-2 |
Macrophage | Blood Cells | Monocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.92e-2 |
Macrophage | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.04e-2 |
Smooth muscle cell | Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 3.63e-2 |
Smooth muscle cell | Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 4.65e-2 |
Macrophage | Blood Cells | Red Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 4.12e-2 |
Macrophage | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 3.15e-3 |
Macrophage | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 6.71e-4 |
Macrophage | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 8.25e-3 |
Oligodendrocyte | Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 1.00e-3 | 3.03e-2 |
Oligodendrocyte | Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 1.00e-4 | 2.38e-2 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 5.00e-2 | 5.38e-3 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-2 | 6.26e-3 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-3 | 6.43e-4 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-4 | 2.45e-3 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-5 | 3.95e-2 |
Macrophage | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 5.00e-2 | 9.08e-4 |
Macrophage | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-2 | 6.75e-5 |
Macrophage | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-3 | 1.92e-4 |
Macrophage | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-4 | 8.55e-5 |
Macrophage | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-5 | 6.28e-5 |
Macrophage | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 5.00e-2 | 4.89e-4 |
Macrophage | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-2 | 1.25e-2 |
Macrophage | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-3 | 3.93e-3 |
Macrophage | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-4 | 3.91e-4 |
Macrophage | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-5 | 1.79e-3 |
Macrophage | Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 7.30e-3 |
Macrophage | Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 1.10e-2 |
Macrophage | Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 4.33e-2 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 1.77e-2 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 1.64e-2 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 3.70e-3 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 2.76e-4 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 9.09e-3 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 2.26e-4 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 1.15e-3 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 8.98e-4 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 1.90e-4 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 2.68e-5 |
Macrophage | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 5.18e-3 |
Macrophage | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 3.56e-4 |
Macrophage | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 5.98e-4 |
Macrophage | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 7.56e-4 |
Macrophage | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 8.94e-5 |
Oligodendrocyte | BMI Age Stratified | BMI Men Age Over 50 | MTC | Winkler | 2015 | NA | 90988 | 5.00e-2 | 4.92e-2 |
Oligodendrocyte | BMI Age Stratified | BMI Women Age Over 50 | MTC | Winkler | 2015 | NA | 106622 | 1.00e-4 | 2.73e-2 |
Macrophage | BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Men Under 50 | MTC | Winkler | 2015 | NA | 43776 | 1.00e-3 | 4.78e-2 |
Smooth muscle cell | BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Women Under 50 | MTC | Winkler | 2015 | NA | 50526 | 5.00e-2 | 2.78e-3 |
Oligodendrocyte | BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Women Under 50 | MTC | Winkler | 2015 | NA | 50526 | 1.00e-2 | 4.19e-2 |
Oligodendrocyte | BMI | BMI European Women | MTC | Locke | 2015 | NA | 132115 | 1.00e-3 | 2.33e-2 |
Oligodendrocyte | BMI Physical Activity Interaction | BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 3.55e-2 |
Oligodendrocyte | BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.04e-2 |
Oligodendrocyte | BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.20e-2 |
Oligodendrocyte | BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 3.22e-2 |
Astrocyte | BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.32e-2 |
Oligodendrocyte | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 5.33e-3 |
Oligodendrocyte | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 4.09e-2 |
Smooth muscle cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 2.25e-2 |
Oligodendrocyte | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 2.29e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 6.94e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 3.90e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.15e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.02e-2 |
Oligodendrocyte | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 3.22e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 4.14e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 5.71e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.15e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 6.38e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.74e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.09e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.87e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 4.82e-3 |
Smooth muscle cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 5.62e-3 |
Oligodendrocyte | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 1.09e-3 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.94e-3 |
Oligodendrocyte | BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.33e-2 |
Oligodendrocyte | BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 2.28e-2 |
Oligodendrocyte | BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 8.70e-3 |
Oligodendrocyte | BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 4.83e-2 |
Oligodendrocyte | BMI Smoking Adjusted | BMI Smoking Adjusted Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 2.79e-2 |
Oligodendrocyte | BMI Smoking Adjusted | BMI Smoking Adjusted Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 2.25e-2 |
Oligodendrocyte | BMI Smoking Adjusted | BMI Smoking Adjusted Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 1.60e-2 |
Oligodendrocyte | BMI Smoking Adjusted | BMI Smoking Adjusted Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 2.10e-2 |
Oligodendrocyte | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 9.93e-4 |
Oligodendrocyte | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-5 | 3.22e-2 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.09e-2 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 4.00e-4 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 4.20e-3 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 6.54e-4 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 4.47e-4 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.47e-2 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 4.49e-4 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 1.87e-4 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 3.29e-3 |
Macrophage | Bone Mineral Density | Lumbar Spine Bone Mineral Density All | MTC | Estrada | 2012 | NA | 31800 | 5.00e-2 | 4.22e-2 |
Smooth muscle cell | Bone Mineral Density | Lumbar Spine Bone Mineral Density All | MTC | Estrada | 2012 | NA | 31800 | 1.00e-5 | 2.61e-2 |
Smooth muscle cell | Bone Mineral Density | Lumbar Spine Bone Mineral Density Men | MTC | Estrada | 2012 | NA | 31800 | 5.00e-2 | 2.01e-2 |
Smooth muscle cell | Bone Mineral Density | Lumbar Spine Bone Mineral Density Men | MTC | Estrada | 2012 | NA | 31800 | 1.00e-2 | 3.60e-2 |
Macrophage | Bone Mineral Density | Lumbar Spine Bone Mineral Density Men | MTC | Estrada | 2012 | NA | 31800 | 1.00e-3 | 2.09e-2 |
Smooth muscle cell | Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 1.00e-3 | 2.19e-2 |
Smooth muscle cell | Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 1.00e-4 | 4.43e-2 |
Smooth muscle cell | Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 1.00e-5 | 4.36e-2 |
Macrophage | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 15 to 30 | MTC | Medina-Gomez | 2018 | NA | 4180 | 5.00e-2 | 4.93e-3 |
Smooth muscle cell | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 30 to 45 | MTC | Medina-Gomez | 2018 | NA | 10062 | 1.00e-4 | 7.18e-3 |
Smooth muscle cell | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 30 to 45 | MTC | Medina-Gomez | 2018 | NA | 10062 | 1.00e-5 | 5.93e-3 |
Smooth muscle cell | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 60 And More | MTC | Medina-Gomez | 2018 | NA | 22504 | 1.00e-2 | 1.99e-2 |
Smooth muscle cell | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 5.00e-2 | 3.05e-3 |
Smooth muscle cell | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-2 | 3.61e-2 |
Smooth muscle cell | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-3 | 3.82e-2 |
Smooth muscle cell | Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 5.00e-2 | 3.31e-2 |
Smooth muscle cell | Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 1.00e-2 | 9.65e-3 |
Oligodendrocyte | Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 5.00e-2 | 2.62e-2 |
Smooth muscle cell | Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-4 | 2.89e-2 |
Smooth muscle cell | Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-5 | 9.45e-3 |
Oligodendrocyte | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 5.00e-2 | 4.92e-3 |
Oligodendrocyte | Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 5.00e-2 | 1.36e-3 |
Oligodendrocyte | Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-2 | 7.26e-4 |
Oligodendrocyte | Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-3 | 2.25e-2 |
Oligodendrocyte | Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-4 | 1.31e-2 |
Oligodendrocyte | Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-5 | 4.29e-2 |
Astrocyte | Cognitive Functions | Memory | MTC | Davies | 2016 | NA | 112067 | 1.00e-3 | 3.23e-2 |
Oligodendrocyte | Cognitive Functions | Reaction Time | MTC | Davies | 2016 | NA | 111483 | 5.00e-2 | 1.19e-3 |
Oligodendrocyte | Cognitive Functions | Reaction Time | MTC | Davies | 2016 | NA | 111483 | 1.00e-2 | 5.58e-4 |
Smooth muscle cell | Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 5.00e-2 | 2.44e-2 |
Smooth muscle cell | Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 4.30e-2 |
Smooth muscle cell | Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 5.00e-2 | 4.79e-2 |
Macrophage | Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-4 | 4.14e-2 |
Macrophage | Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-5 | 6.51e-3 |
Smooth muscle cell | Diarrhoeal Disease | Diarrhea Age 1 | MTC | Bustamante | 2016 | 2693 | 3065 | 1.00e-3 | 3.99e-3 |
Smooth muscle cell | Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 2 | MTC | Bustamante | 2016 | 990 | 5243 | 1.00e-3 | 4.36e-2 |
Macrophage | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 5.00e-2 | 2.52e-4 |
Macrophage | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-3 | 9.35e-3 |
Smooth muscle cell | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-2 | 2.01e-2 |
Smooth muscle cell | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-3 | 3.15e-2 |
Macrophage | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight Men | MTC | Chu | 2017 | NA | 3640 | 5.00e-2 | 3.70e-3 |
Macrophage | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight Men | MTC | Chu | 2017 | NA | 3640 | 1.00e-2 | 4.29e-2 |
Smooth muscle cell | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight Men | MTC | Chu | 2017 | NA | 3640 | 5.00e-2 | 3.23e-2 |
Oligodendrocyte | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 3640 | 5.00e-2 | 4.42e-2 |
Astrocyte | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 3640 | 1.00e-2 | 8.13e-3 |
Oligodendrocyte | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 1.00e-3 | 2.10e-3 |
Oligodendrocyte | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 5.00e-2 | 4.76e-2 |
Oligodendrocyte | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-2 | 7.10e-4 |
Astrocyte | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 3.23e-2 |
Smooth muscle cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-2 | 1.03e-2 |
Oligodendrocyte | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 1.00e-2 | 9.94e-3 |
Astrocyte | Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 2.11e-2 |
Oligodendrocyte | Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Women | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 9.78e-3 |
Oligodendrocyte | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14780 | 5.00e-2 | 3.22e-2 |
Astrocyte | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7381 | 5.00e-2 | 3.10e-2 |
Oligodendrocyte | Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 5.00e-2 | 3.02e-2 |
Oligodendrocyte | Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 1.00e-2 | 3.74e-2 |
Oligodendrocyte | Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 1.00e-3 | 2.61e-2 |
Smooth muscle cell | Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 5.00e-2 | 4.32e-2 |
Macrophage | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 6.20e-3 |
Astrocyte | Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 2.79e-2 |
Oligodendrocyte | Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 4.98e-3 |
Oligodendrocyte | Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 5.00e-2 | 4.82e-3 |
Oligodendrocyte | Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-2 | 8.48e-3 |
Oligodendrocyte | Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-3 | 1.46e-2 |
Oligodendrocyte | Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-4 | 2.24e-2 |
Oligodendrocyte | Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-5 | 4.90e-2 |
Oligodendrocyte | Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 4.20e-2 |
Oligodendrocyte | Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 2.08e-2 |
Oligodendrocyte | Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-3 | 5.23e-4 |
Oligodendrocyte | Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 2.40e-3 |
Oligodendrocyte | Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 3.34e-4 |
Oligodendrocyte | Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-4 | 2.20e-2 |
Macrophage | Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 5.00e-2 | 2.12e-2 |
Macrophage | Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-2 | 4.90e-2 |
Smooth muscle cell | Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 5.00e-2 | 1.45e-2 |
Oligodendrocyte | Facial Shape | Mod10 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.45e-2 |
Macrophage | Facial Shape | Mod15 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 4.36e-2 |
Macrophage | Facial Shape | Mod17 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.95e-2 |
Macrophage | Facial Shape | Mod17 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.49e-3 |
Macrophage | Facial Shape | Mod18 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.66e-2 |
Oligodendrocyte | Facial Shape | Mod2 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.91e-2 |
Oligodendrocyte | Facial Shape | Mod21 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.58e-2 |
Macrophage | Facial Shape | Mod23 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.56e-2 |
Smooth muscle cell | Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.18e-2 |
Macrophage | Facial Shape | Mod27 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.84e-2 |
Macrophage | Facial Shape | Mod34 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.70e-2 |
Macrophage | Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.47e-3 |
Macrophage | Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.09e-4 |
Smooth muscle cell | Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.44e-2 |
Macrophage | Facial Shape | Mod37 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.51e-2 |
Smooth muscle cell | Facial Shape | Mod39 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.49e-2 |
Macrophage | Facial Shape | Mod4 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.55e-2 |
Oligodendrocyte | Facial Shape | Mod40 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.42e-2 |
Oligodendrocyte | Facial Shape | Mod40 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.42e-4 |
Macrophage | Facial Shape | Mod40 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 4.36e-2 |
Oligodendrocyte | Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.06e-2 |
Astrocyte | Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.06e-2 |
Astrocyte | Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 9.75e-3 |
Oligodendrocyte | Facial Shape | Mod43 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.65e-2 |
Oligodendrocyte | Facial Shape | Mod43 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.69e-2 |
Astrocyte | Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.94e-3 |
Astrocyte | Facial Shape | Mod56 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.66e-2 |
Macrophage | Facial Shape | Mod8 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.71e-3 |
Macrophage | Forced Expiratory Volume | Forced Expiratory Volume | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-5 | 3.58e-2 |
Macrophage | Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 5.00e-2 | 6.05e-4 |
Macrophage | Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 1.00e-2 | 2.69e-2 |
Smooth muscle cell | Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-2 | 3.41e-2 |
Macrophage | Gestational Weight Gain | Late Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 8641 | 5.00e-2 | 2.35e-2 |
Macrophage | Gestational Weight Gain | Late Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 7681 | 5.00e-2 | 4.65e-2 |
Macrophage | Gestational Weight Gain | Late Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 7681 | 1.00e-3 | 2.97e-2 |
Oligodendrocyte | Gestational Weight Gain | Total Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 16434 | 5.00e-2 | 4.13e-2 |
Macrophage | Glucose Stimulated Insulin Secretion | AUC Insulin | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.28e-2 |
Macrophage | Glucose Stimulated Insulin Secretion | AUC Insulin | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 4.91e-2 |
Macrophage | Glucose Stimulated Insulin Secretion | AUC Insulin Over AUC Glucose | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 7.52e-4 |
Macrophage | Glucose Stimulated Insulin Secretion | AUC Insulin Over AUC Glucose | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 1.14e-2 |
Macrophage | Glucose Stimulated Insulin Secretion | Corrected Insulin Response | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 1.46e-2 |
Astrocyte | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 4.80e-2 |
Astrocyte | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 3.59e-2 |
Oligodendrocyte | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 3.22e-2 |
Astrocyte | Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 1.58e-2 |
Smooth muscle cell | Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 1.58e-2 |
Smooth muscle cell | Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 5.91e-3 |
Smooth muscle cell | Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 2.66e-2 |
Smooth muscle cell | Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 3.40e-2 |
Oligodendrocyte | Glycemic Traits BMI Corrected | Fasting Glucose | MTC | Manning | 2012 | NA | 58074 | 5.00e-2 | 9.05e-3 |
Oligodendrocyte | Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 1.00e-2 | 1.25e-2 |
Oligodendrocyte | Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 1.00e-3 | 2.49e-2 |
Oligodendrocyte | Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 1.00e-4 | 3.86e-2 |
Macrophage | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-2 | 4.24e-2 |
Macrophage | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 8.55e-3 |
Macrophage | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 5.00e-2 | 6.04e-5 |
Macrophage | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-2 | 4.33e-5 |
Macrophage | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-3 | 1.59e-3 |
Macrophage | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-4 | 3.24e-3 |
Macrophage | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-5 | 5.98e-4 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 5.00e-2 | 2.73e-6 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-2 | 4.09e-6 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-3 | 1.57e-4 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-4 | 3.74e-5 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-5 | 6.79e-6 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 5.00e-2 | 2.16e-5 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-2 | 1.99e-7 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-3 | 1.16e-5 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-4 | 2.74e-5 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-5 | 1.60e-7 |
Astrocyte | Insulin Secretion | Acute Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2087 | 5.00e-2 | 4.83e-2 |
Astrocyte | Insulin Secretion | Acute Insulin Response Adjusted For Insulin Sensitivity | MTC | Wood | 2017 | NA | 2087 | 5.00e-2 | 4.27e-2 |
Astrocyte | Insulin Secretion | Disposition Index | MTC | Wood | 2017 | NA | 2042 | 5.00e-2 | 2.36e-3 |
Oligodendrocyte | Insulin Secretion | Disposition Index Adjusted For BMI | MTC | Wood | 2017 | NA | 2042 | 5.00e-2 | 4.52e-2 |
Oligodendrocyte | Insulin Secretion | Disposition Index Adjusted For BMI | MTC | Wood | 2017 | NA | 2042 | 1.00e-2 | 4.15e-3 |
Astrocyte | Insulin Secretion | Disposition Index Adjusted For BMI | MTC | Wood | 2017 | NA | 2042 | 5.00e-2 | 8.26e-3 |
Oligodendrocyte | Insulin Secretion | Insulin Secretion Rate | MTC | Wood | 2017 | NA | 527 | 1.00e-2 | 8.27e-4 |
Oligodendrocyte | Insulin Secretion | Insulin Secretion Rate Adjusted For BMI | MTC | Wood | 2017 | NA | 527 | 1.00e-2 | 1.17e-2 |
Astrocyte | Insulin Secretion | Peak Insulin Response | MTC | Wood | 2017 | NA | 2159 | 5.00e-2 | 4.32e-2 |
Astrocyte | Insulin Secretion | Peak Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 5.00e-2 | 1.69e-2 |
Astrocyte | Insulin Secretion | Peak Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 1.00e-2 | 2.95e-2 |
Astrocyte | Insulin Secretion | Peak Insulin Response Adjusted For Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 5.00e-2 | 2.58e-3 |
Astrocyte | Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 3.48e-2 |
Smooth muscle cell | Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 1.33e-2 |
Macrophage | Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 1.00e-3 | 4.78e-2 |
Astrocyte | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 1.15e-2 |
Macrophage | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 1.00e-3 | 4.79e-2 |
Astrocyte | Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 1.00e-3 | 4.55e-3 |
Smooth muscle cell | Ischaemic Stroke | All Stroke | MTC | Traylor | 2012 | 10210 | 12285 | 5.00e-2 | 1.43e-2 |
Astrocyte | Ischaemic Stroke | All Stroke | MTC | Traylor | 2012 | 10210 | 12285 | 1.00e-3 | 4.36e-2 |
Smooth muscle cell | Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 5.00e-2 | 4.32e-2 |
Astrocyte | Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-2 | 2.83e-2 |
Astrocyte | Ischaemic Stroke | Large Vessel Disease | MTC | Traylor | 2012 | 1877 | 12285 | 5.00e-2 | 1.71e-2 |
Oligodendrocyte | Kidney Function | CKDi | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 3.95e-2 |
Oligodendrocyte | Kidney Function | CKDi | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 1.72e-2 |
Oligodendrocyte | Kidney Function | CKDi | MTC | Gorski | 2015 | NA | 45530 | 1.00e-3 | 3.40e-2 |
Oligodendrocyte | Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 2.55e-2 |
Oligodendrocyte | Kidney Function | eGFR Decline With Chronic Kidney Disease | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 2.20e-2 |
Oligodendrocyte | Kidney Function | eGFR Decline With Chronic Kidney Disease | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 2.13e-2 |
Macrophage | Kidney Function | eGFR Decline With Chronic Kidney Disease | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 2.13e-2 |
Macrophage | Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-2 | 4.95e-2 |
Oligodendrocyte | Kidney Function | Chronic Kidney Disease | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-2 | 1.46e-2 |
Smooth muscle cell | Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-2 | 2.95e-2 |
Astrocyte | Lean Body Mass | Appendicular Lean Mass | MTC | Zillikens | 2017 | NA | 28330 | 1.00e-2 | 5.20e-3 |
Macrophage | Lean Body Mass | Whole Body Lean Mass | MTC | Zillikens | 2017 | NA | 38292 | 1.00e-4 | 4.36e-2 |
Smooth muscle cell | Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 1.00e-2 | 1.51e-2 |
Smooth muscle cell | Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 1.00e-3 | 2.29e-2 |
Smooth muscle cell | Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 6.89e-3 |
Macrophage | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 5.00e-2 | 2.00e-2 |
Macrophage | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-2 | 3.96e-3 |
Oligodendrocyte | Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 4.70e-2 |
Oligodendrocyte | Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-2 | 1.49e-2 |
Oligodendrocyte | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-3 | 2.61e-2 |
Oligodendrocyte | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-5 | 2.97e-2 |
Smooth muscle cell | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-3 | 1.04e-2 |
Smooth muscle cell | Lipoprotein Concentrations | Triglycerides | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 3.27e-3 |
Oligodendrocyte | Longevity | Age 90 Or Greater | MTC | Deelen | 2014 | 5406 | 15112 | 5.00e-2 | 9.64e-3 |
Astrocyte | Lymphocyte Subsets | CD19 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.61e-2 |
Macrophage | Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.06e-3 |
Macrophage | Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 9.09e-3 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 1.62e-4 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 2.31e-7 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 3.16e-12 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 2.23e-11 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 8.19e-11 |
Macrophage | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.70e-3 |
Macrophage | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.57e-5 |
Macrophage | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.42e-4 |
Macrophage | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 2.47e-3 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 1.05e-3 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 3.80e-6 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.21e-9 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 1.98e-8 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 1.25e-9 |
Oligodendrocyte | TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 5.29e-3 |
Astrocyte | TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 2.17e-2 |
Oligodendrocyte | Personality Big5 | Openness To Experience | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 3.11e-2 |
Astrocyte | Personality Big5 | Openness To Experience | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 3.98e-2 |
Macrophage | Pubertal Anthropometrics | Height 10 Year Females | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 6.86e-4 |
Oligodendrocyte | Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 3.20e-2 |
Astrocyte | Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 9.56e-3 |
Astrocyte | Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 2.29e-2 |
Astrocyte | Pubertal Anthropometrics | Total Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 2.98e-2 |
Astrocyte | Reproductive Behavior | Age First Birth Pooled | ETC | Barban | 2016 | NA | 238064 | 1.00e-2 | 1.83e-2 |
Macrophage | Reproductive Behavior | Age First Birth Pooled | ETC | Barban | 2016 | NA | 238064 | 1.00e-5 | 4.36e-2 |
Oligodendrocyte | Reproductive Behavior | Number Children Even Born Pooled | MTC | Barban | 2016 | NA | 329139 | 5.00e-2 | 4.85e-3 |
Oligodendrocyte | Reproductive Behavior | Number Children Even Born Pooled | MTC | Barban | 2016 | NA | 329139 | 1.00e-2 | 3.37e-2 |
Oligodendrocyte | Reproductive Behavior | Number Children Ever Born Female | MTC | Barban | 2016 | NA | 225230 | 5.00e-2 | 4.30e-4 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 5.00e-2 | 2.00e-5 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-2 | 2.47e-7 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 4.73e-8 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 2.83e-12 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 5.51e-14 |
Oligodendrocyte | Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 5.00e-2 | 4.38e-2 |
Oligodendrocyte | Stroke (ischemic) | All Ischemic Stroke | MTC | Traylor | 2017 | 12389 | 62004 | 5.00e-2 | 2.58e-2 |
Astrocyte | Stroke (ischemic) | Large Artery Stroke | MTC | Traylor | 2017 | 2167 | 62004 | 5.00e-2 | 1.38e-2 |
Macrophage | Smoking | Cigarettes Per Day | ETC | Furberg | 2010 | NA | 38181 | 1.00e-3 | 1.35e-2 |
Oligodendrocyte | Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 2.89e-4 |
Oligodendrocyte | Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 1.00e-2 | 2.59e-3 |
Oligodendrocyte | Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 1.00e-3 | 1.78e-3 |
Smooth muscle cell | Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 4.11e-2 |
Smooth muscle cell | Social Deprivation | Household Income One Person Per Household | MTC | Hill | 2016 | NA | 112005 | 5.00e-2 | 2.49e-2 |
Macrophage | Social Deprivation | Townsend Score | MTC | Hill | 2016 | NA | 96900 | 1.00e-3 | 4.01e-3 |
Astrocyte | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 1.19e-3 |
Astrocyte | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 6.19e-4 |
Astrocyte | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 1.14e-3 |
Macrophage | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 1.58e-2 |
Oligodendrocyte | Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-4 | 1.88e-2 |
Macrophage | Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 9.66e-3 |
Macrophage | Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 1.46e-2 |
Astrocyte | Statin Efficacy | Delta TG | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 1.93e-2 |
Astrocyte | Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 1.02e-2 |
Astrocyte | Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 8.06e-3 |
Oligodendrocyte | Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-3 | 4.92e-2 |
Astrocyte | Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-5 | 3.23e-2 |
Macrophage | Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-3 | 2.68e-2 |
Oligodendrocyte | Waist Format 1 | Hip Circumference European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 2.66e-2 |
Oligodendrocyte | Waist Format 1 | Hip Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 4.82e-2 |
Oligodendrocyte | Waist Format 1 | Hip Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-4 | 3.13e-2 |
Oligodendrocyte | Waist Format 1 | Hip Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-5 | 4.00e-2 |
Oligodendrocyte | Waist Format 1 | Waist Circumference European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 4.96e-2 |
Oligodendrocyte | Waist Format 1 | Waist Circumference European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 3.59e-2 |
Oligodendrocyte | Waist Format 1 | Waist Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 9.77e-3 |
Oligodendrocyte | Waist Format 1 | Waist Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-5 | 4.43e-2 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 8.36e-3 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 5.17e-4 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 3.23e-2 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 4.61e-2 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 9.64e-3 |
Oligodendrocyte | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 1.83e-2 |
Oligodendrocyte | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 1.10e-2 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 1.16e-2 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 2.24e-3 |
Oligodendrocyte | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 2.68e-2 |
Oligodendrocyte | Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 1.68e-2 |
Oligodendrocyte | Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 2.77e-2 |
Oligodendrocyte | Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 2.98e-3 |
Smooth muscle cell | Waist Format 2 | Waist Hip Ratio Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 7.57e-3 |
Oligodendrocyte | SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-2 | 1.61e-2 |
Oligodendrocyte | SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-3 | 1.38e-2 |
Oligodendrocyte | SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-4 | 4.70e-3 |
Oligodendrocyte | SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-5 | 2.73e-2 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 5.40e-5 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-2 | 4.96e-7 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 1.18e-9 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 7.02e-12 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 2.32e-12 |
Smooth muscle cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 3.35e-2 |
Astrocyte | PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 5.00e-2 | 3.66e-2 |
Oligodendrocyte | COL | SSGAC_College | ETC | Rietveld | 2013 | NA | 101069 | 5.00e-2 | 2.02e-2 |
Oligodendrocyte | COL | SSGAC_College | ETC | Rietveld | 2013 | NA | 101069 | 1.00e-2 | 5.73e-3 |
Macrophage | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 5.00e-2 | 1.04e-2 |
Macrophage | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 9.93e-3 |
Macrophage | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 1.17e-3 |
Macrophage | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 1.35e-2 |
Macrophage | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 2.87e-3 |
Macrophage | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 5.00e-2 | 9.50e-4 |
Macrophage | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 7.03e-3 |
Macrophage | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 9.14e-3 |
Macrophage | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 1.25e-2 |
Macrophage | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 2.37e-2 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 5.00e-2 | 9.98e-9 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-2 | 3.74e-7 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-3 | 1.83e-7 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 3.14e-7 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 5.81e-10 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 1.43e-8 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-2 | 9.41e-9 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-3 | 6.72e-10 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 9.92e-14 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 5.95e-14 |
Macrophage | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 1.68e-2 |
Macrophage | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-4 | 1.08e-3 |
Macrophage | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-5 | 1.89e-3 |
Smooth muscle cell | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 3.16e-2 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 5.00e-2 | 2.01e-4 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-2 | 2.61e-7 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-3 | 5.32e-10 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 1.26e-9 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 9.25e-12 |
Astrocyte | AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 5.00e-2 | 8.26e-3 |
Smooth muscle cell | AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 5.00e-2 | 3.07e-2 |
Smooth muscle cell | AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 1.00e-2 | 2.58e-2 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 5.00e-2 | 1.71e-6 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-2 | 6.35e-7 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 4.06e-7 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 2.11e-9 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 1.32e-12 |
Oligodendrocyte | SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-2 | 1.83e-2 |
Oligodendrocyte | SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-3 | 1.31e-2 |
Oligodendrocyte | SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-5 | 3.10e-2 |
Macrophage | CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 5.00e-2 | 4.06e-2 |
Macrophage | CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-2 | 1.77e-2 |
Macrophage | CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-3 | 1.58e-4 |
Macrophage | CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-4 | 1.09e-5 |
Macrophage | CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-5 | 3.57e-4 |
Macrophage | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 5.00e-2 | 6.69e-3 |
Macrophage | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-2 | 1.20e-3 |
Macrophage | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-3 | 2.94e-2 |
Macrophage | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-4 | 1.95e-2 |
Macrophage | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-5 | 2.37e-2 |
Oligodendrocyte | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-4 | 1.95e-2 |
Astrocyte | Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 5.00e-2 | 4.62e-2 |
Smooth muscle cell | Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 5.00e-2 | 3.28e-2 |
Smooth muscle cell | Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 1.00e-2 | 3.23e-2 |
Oligodendrocyte | Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 1.00e-2 | 3.23e-2 |
Macrophage | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 5.00e-2 | 2.36e-2 |
Macrophage | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-3 | 4.20e-3 |
Smooth muscle cell | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 5.00e-2 | 3.22e-2 |
Oligodendrocyte | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-4 | 2.49e-2 |
Astrocyte | Parkinsons | Parkinsons disease, age of onset | ETC | Blauwendraat | 2019 | NA | 17996 | 5.00e-2 | 2.87e-2 |
Smooth muscle cell | Active | Time to most active 10 hours | ETC | Jones | 2019 | NA | 85670 | 5.00e-2 | 2.19e-2 |
Oligodendrocyte | Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 4.68e-2 |
Astrocyte | Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 4.68e-2 |
Astrocyte | Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 1.14e-2 |
Oligodendrocyte | Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 2.49e-2 |
Astrocyte | Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 7.91e-3 |
Astrocyte | Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 4.06e-2 |
Astrocyte | Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 1.05e-2 |
Smooth muscle cell | Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 4.89e-2 |
Smooth muscle cell | Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 3.93e-3 |
Smooth muscle cell | Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 2.77e-2 |
Macrophage | Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 1.99e-2 |
Oligodendrocyte | Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 4.39e-2 |
Macrophage | Facial attractiveness | Facial attractiveness, female raters | ETC | Hu | 2019 | NA | 3928 | 1.00e-2 | 1.10e-2 |
Macrophage | Facial attractiveness | Facial attractiveness of females, female raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 1.61e-2 |
Smooth muscle cell | Facial attractiveness | Facial attractiveness of females, female raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 3.74e-2 |
Macrophage | Facial attractiveness | Facial attractiveness of females, male raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 1.10e-2 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 5.00e-2 | 2.59e-5 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-2 | 2.39e-5 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-3 | 1.15e-5 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-4 | 8.73e-7 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-5 | 2.21e-9 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 5.00e-2 | 9.98e-5 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-2 | 3.43e-6 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-3 | 4.11e-7 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-4 | 8.67e-6 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 5.61e-8 |
Smooth muscle cell | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 5.00e-2 | 4.52e-2 |
Oligodendrocyte | Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 6.10e-3 |
Astrocyte | Neuroticism | Worry-vulnerability-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 1.14e-2 |
Astrocyte | Neuroticism | Anxiety-tension-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 1.14e-2 |
Macrophage | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-3 | 4.72e-2 |
Macrophage | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-4 | 2.10e-2 |
Macrophage | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-5 | 8.54e-3 |
Oligodendrocyte | Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 5.00e-2 | 2.26e-3 |
Oligodendrocyte | Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 5.00e-2 | 7.99e-3 |
Macrophage | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 5.00e-2 | 2.81e-2 |
Macrophage | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-3 | 4.19e-2 |
Macrophage | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-4 | 9.49e-6 |
Macrophage | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-5 | 7.61e-6 |
Oligodendrocyte | Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 5.00e-2 | 5.10e-3 |
Oligodendrocyte | Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-2 | 2.18e-2 |
Astrocyte | Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-2 | 6.11e-3 |
Astrocyte | Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-3 | 3.23e-2 |
Oligodendrocyte | Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-2 | 1.18e-2 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 1.71e-6 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 6.40e-7 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-3 | 8.55e-8 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 1.40e-7 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-5 | 3.38e-6 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 5.00e-2 | 4.24e-3 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-2 | 1.14e-4 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-3 | 1.27e-6 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-4 | 7.93e-8 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-5 | 4.79e-8 |
Astrocyte | Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 9.85e-3 |
Macrophage | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 4.31e-2 |
Astrocyte | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 9.63e-3 |
Oligodendrocyte | Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 2.58e-2 |
Oligodendrocyte | Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 5.92e-3 |
Macrophage | Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-5 | 4.79e-2 |
Oligodendrocyte | Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 5.00e-2 | 4.16e-2 |
Macrophage | Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 1.00e-5 | 2.50e-2 |
Smooth muscle cell | Osteoarthritis | Knee osteoarthritis | ETC | Tachmazidou | 2019 | 24955 | 376169 | 5.00e-2 | 2.03e-2 |
Astrocyte | Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 5.00e-2 | 2.63e-2 |
Astrocyte | Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 5.00e-2 | 1.98e-2 |
Astrocyte | Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-2 | 2.14e-2 |
Astrocyte | Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-3 | 4.17e-2 |
Astrocyte | Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-4 | 1.32e-2 |
Astrocyte | Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-5 | 1.12e-2 |
Astrocyte | Smoking | Age of smoking initiation | ETC | Liua | 2019 | NA | 341427 | 5.00e-2 | 1.68e-2 |
Macrophage | Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-4 | 2.25e-2 |
Macrophage | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 5.00e-2 | 3.34e-7 |
Macrophage | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 2.63e-4 |
Macrophage | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-3 | 1.93e-3 |
Macrophage | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 5.00e-2 | 1.11e-3 |
Macrophage | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-2 | 9.43e-4 |
Macrophage | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-3 | 1.14e-4 |
Macrophage | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-4 | 7.56e-6 |
Macrophage | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-5 | 2.24e-3 |
Oligodendrocyte | Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 3.56e-2 |
Astrocyte | Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 4.64e-2 |
Oligodendrocyte | Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 4.50e-3 |
Oligodendrocyte | Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 6.17e-3 |
Oligodendrocyte | Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 2.07e-2 |
Oligodendrocyte | Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 1.00e-5 | 1.05e-2 |
Oligodendrocyte | Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 1.02e-2 |
Astrocyte | Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 4.81e-2 |
Oligodendrocyte | Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 4.39e-4 |
Oligodendrocyte | Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 4.34e-3 |
Oligodendrocyte | Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-4 | 2.89e-2 |
Astrocyte | Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 5.00e-2 | 1.02e-2 |
Smooth muscle cell | Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 5.00e-2 | 4.74e-2 |
Smooth muscle cell | Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 1.00e-2 | 1.62e-2 |
Smooth muscle cell | Heart failure | Heart failure | ETC | Aragam | 2018 | 6504 | 387652 | 1.00e-3 | 4.85e-3 |
Macrophage | Brain volume | Dentate gyrus molecular layer volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.71e-3 |
Smooth muscle cell | Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 3.98e-2 |
Oligodendrocyte | Presubiculum volume | Presubiculum volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.14e-3 |
Oligodendrocyte | Presubiculum volume | Presubiculum volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.12e-2 |
Smooth muscle cell | IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-2 | 2.47e-2 |
Smooth muscle cell | IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-3 | 2.49e-2 |
Oligodendrocyte | ACR | Urinary albumin to creatinine ratio | ETC | Zanetti | 2019 | NA | 218759 | 5.00e-2 | 2.75e-2 |
Oligodendrocyte | Na/C | Urinary sodium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218450 | 5.00e-2 | 2.67e-2 |
Oligodendrocyte | AUDIT-C | Alcohol-Use-Disorder-Identification-Test-Consumption | ETC | Kranzler | 2019 | NA | 200680 | 5.00e-2 | 1.17e-2 |
Astrocyte | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 2.91e-2 |
Macrophage | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-3 | 2.87e-3 |
Macrophage | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-4 | 1.67e-2 |
Macrophage | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-5 | 5.91e-3 |
Macrophage | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-2 | 3.03e-2 |
Macrophage | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-3 | 4.56e-3 |
Macrophage | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-4 | 2.75e-4 |
Macrophage | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-5 | 2.80e-5 |
Macrophage | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 1.00e-4 | 6.51e-3 |
Macrophage | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 1.00e-5 | 1.55e-2 |
Macrophage | Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 5.00e-2 | 2.50e-2 |
Macrophage | Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-2 | 9.25e-3 |
Smooth muscle cell | Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-2 | 2.23e-2 |
Macrophage | Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-4 | 1.97e-2 |
Macrophage | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 5.00e-2 | 3.46e-2 |
Macrophage | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-2 | 1.46e-2 |
Macrophage | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-5 | 3.12e-2 |
Macrophage | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 5.00e-2 | 4.40e-6 |
Macrophage | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-2 | 8.01e-8 |
Macrophage | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-3 | 3.67e-8 |
Macrophage | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-4 | 1.69e-9 |
Macrophage | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-5 | 6.79e-10 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 5.00e-2 | 2.20e-4 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 8.10e-10 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-3 | 1.87e-9 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-4 | 2.06e-10 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 1.27e-11 |
Macrophage | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 5.00e-2 | 7.69e-3 |
Macrophage | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-2 | 7.65e-4 |
Macrophage | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-3 | 5.32e-4 |
Macrophage | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-4 | 8.33e-3 |
Oligodendrocyte | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-3 | 1.03e-2 |
Macrophage | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 5.00e-2 | 3.09e-4 |
Macrophage | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 2.01e-5 |
Macrophage | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-3 | 3.28e-4 |
Macrophage | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-4 | 4.78e-5 |
Macrophage | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-5 | 4.05e-5 |
Macrophage | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-2 | 3.66e-2 |
Macrophage | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-4 | 3.92e-2 |
Macrophage | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-5 | 2.09e-3 |
Macrophage | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 5.00e-2 | 3.01e-2 |
Macrophage | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-2 | 7.42e-3 |
Macrophage | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-3 | 1.42e-2 |
Macrophage | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-5 | 2.21e-2 |
Macrophage | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 5.00e-2 | 5.48e-3 |
Macrophage | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-2 | 5.08e-3 |
Macrophage | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-3 | 3.52e-5 |
Macrophage | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-4 | 5.61e-7 |
Macrophage | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-5 | 6.54e-6 |
Astrocyte | Medication use | Medication use (antimigraine preparations) | ETC | Wu Y | 2019 | 5,521 | 114,323 | 1.00e-5 | 2.97e-2 |
Macrophage | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 5.00e-2 | 4.88e-3 |
Macrophage | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-2 | 3.38e-4 |
Macrophage | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-3 | 9.51e-6 |
Macrophage | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-4 | 9.80e-7 |
Macrophage | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-5 | 1.86e-7 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 5.00e-2 | 6.34e-4 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-2 | 8.87e-5 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 1.74e-4 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 1.92e-7 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 7.98e-9 |
Macrophage | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 5.00e-2 | 4.52e-5 |
Macrophage | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 5.67e-5 |
Macrophage | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-3 | 3.83e-5 |
Macrophage | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-4 | 8.17e-5 |
Smooth muscle cell | Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 1.67e-2 |
Smooth muscle cell | Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-2 | 4.47e-3 |
Macrophage | Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 5.00e-2 | 3.44e-2 |
Macrophage | Renal cell carcinoma | Renal cell carcinoma male | ETC | Laskar RS | 2019 | 3,227 | 4,916 | 5.00e-2 | 8.93e-3 |
Astrocyte | Renal cell carcinoma | Renal cell carcinoma male | ETC | Laskar RS | 2019 | 3,227 | 4,916 | 5.00e-2 | 3.66e-3 |
Smooth muscle cell | Renal cell carcinoma | Renal cell carcinoma male | ETC | Laskar RS | 2019 | 3,227 | 4,916 | 1.00e-2 | 3.23e-2 |
Oligodendrocyte | Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 3.62e-2 |
Smooth muscle cell | Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 6.78e-3 |
Smooth muscle cell | Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-3 | 2.57e-2 |
Astrocyte | Nonalcoholic Liver disease | Nonalcoholic fatty liver disease | ETC | Namjou B | 2019 | 1,106 | 8,571 | 5.00e-2 | 9.08e-3 |
Smooth muscle cell | Autistic traits score | Autistic traits score (Social and Communication Disorders Checklist) | ETC | Massrali A | 2019 | NA | 5,628 | 1.00e-2 | 2.22e-2 |
Oligodendrocyte | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 5.00e-2 | 1.65e-2 |
Macrophage | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 5.00e-2 | 3.86e-2 |
Astrocyte | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 5.00e-2 | 1.65e-2 |
Macrophage | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 9,844 | 20,403 | 1.00e-2 | 4.79e-2 |
Oligodendrocyte | Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 5.00e-2 | 3.70e-2 |
Astrocyte | Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 5.00e-2 | 2.61e-2 |
Astrocyte | Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 1.00e-2 | 8.97e-3 |
Oligodendrocyte | Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 5.00e-2 | 3.48e-2 |
Macrophage | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 5.00e-2 | 2.95e-2 |
Macrophage | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-3 | 1.49e-2 |
Macrophage | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-4 | 4.06e-3 |
Macrophage | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-5 | 4.16e-3 |
Macrophage | same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-2 | 4.02e-2 |
Oligodendrocyte | same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 5.00e-2 | 1.74e-2 |
Macrophage | same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 3.00e-2 |
Astrocyte | same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 3.00e-2 |
Oligodendrocyte | Occipital lobe volume | Occipital lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-3 | 4.07e-2 |
Oligodendrocyte | Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 3.51e-2 |
Oligodendrocyte | Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-2 | 3.56e-2 |
Astrocyte | Frontal lobe volume | Frontal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 3.26e-2 |
Oligodendrocyte | Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-3 | 4.46e-2 |
Oligodendrocyte | Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-4 | 8.55e-3 |
Oligodendrocyte | Visceral adipose tissue | Predicted visceral adipose tissue Both | ETC | Karlsson T | 2019 | NA | 325,153 | 1.00e-5 | 4.59e-2 |
Macrophage | Birth | Spontaneous preterm birth (preterm birth) | ETC | Liu X | 2019 | 4,775 | 60,148 | 5.00e-2 | 1.28e-2 |
Oligodendrocyte | Birth | Spontaneous preterm birth (preterm birth) | ETC | Liu X | 2019 | 4,775 | 60,148 | 1.00e-3 | 4.90e-2 |
Macrophage | Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-4 | 3.00e-2 |
Macrophage | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 5.00e-2 | 1.85e-2 |
Macrophage | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-2 | 3.80e-2 |
Macrophage | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-3 | 6.25e-4 |
Macrophage | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-4 | 2.07e-4 |
Macrophage | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-5 | 1.36e-4 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 5.00e-2 | 3.95e-5 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-2 | 1.92e-5 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-3 | 1.10e-5 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-4 | 1.85e-4 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-5 | 3.73e-3 |
Smooth muscle cell | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 5.00e-2 | 1.27e-2 |
Macrophage | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-2 | 3.72e-2 |
Macrophage | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-4 | 2.13e-2 |
Macrophage | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-5 | 5.34e-3 |
Macrophage | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-3 | 3.24e-2 |
Macrophage | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-4 | 1.07e-3 |
Macrophage | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-5 | 4.85e-4 |
Oligodendrocyte | BMI | Body mass index | ETC | Pulit SL | 2019 | NA | 374,756 | 1.00e-4 | 2.57e-2 |
Macrophage | Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 5.00e-2 | 9.53e-3 |
Macrophage | Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 1.00e-2 | 2.89e-2 |
Oligodendrocyte | AD | Alzheimer's disease | ETC | Moreno-Grau S | 2019 | 4,120 | 3,289 | 1.00e-3 | 2.68e-2 |
Macrophage | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 5.00e-2 | 2.31e-2 |
Macrophage | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 1.33e-3 |
Macrophage | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-3 | 1.47e-6 |
Macrophage | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-4 | 1.49e-3 |
Macrophage | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-5 | 9.49e-4 |
Macrophage | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-2 | 4.93e-2 |
Macrophage | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-3 | 6.90e-3 |
Macrophage | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-4 | 2.08e-3 |
Macrophage | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-5 | 8.72e-3 |
Macrophage | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-2 | 2.95e-2 |
Macrophage | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-3 | 2.52e-3 |
Macrophage | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-4 | 4.96e-5 |
Macrophage | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-5 | 2.85e-5 |
Oligodendrocyte | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 5.00e-2 | 2.40e-2 |
Macrophage | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-2 | 4.31e-3 |
Macrophage | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-3 | 7.30e-4 |
Macrophage | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-4 | 6.70e-3 |
Macrophage | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-5 | 3.05e-3 |
Macrophage | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 5.00e-2 | 1.38e-2 |
Macrophage | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-2 | 1.37e-3 |
Macrophage | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-3 | 1.41e-5 |
Macrophage | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-4 | 6.28e-5 |
Macrophage | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-5 | 9.86e-5 |
Oligodendrocyte | Height | Height variance | ETC | Wang H | 2019 | NA | 347,086 | 5.00e-2 | 5.52e-3 |
Astrocyte | Height | Height variance | ETC | Wang H | 2019 | NA | 347,086 | 1.00e-2 | 7.71e-3 |
Smooth muscle cell | Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 5.00e-2 | 3.15e-2 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 5.00e-2 | 2.18e-5 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-2 | 1.49e-9 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-3 | 1.54e-8 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-4 | 1.05e-7 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-5 | 3.83e-8 |
Astrocyte | Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 5.00e-2 | 9.81e-5 |
Astrocyte | Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-2 | 8.95e-4 |
Oligodendrocyte | Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-2 | 4.29e-2 |
Smooth muscle cell | Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-3 | 2.29e-2 |
Smooth muscle cell | Heavy menstrual bleeding | Heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 9,813 | 210,946 | 5.00e-2 | 4.39e-2 |
Astrocyte | Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 5.00e-2 | 4.27e-2 |
Astrocyte | Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-2 | 4.59e-2 |
Astrocyte | Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-3 | 4.78e-2 |
Macrophage | Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-3 | 4.78e-2 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 5.00e-2 | 1.55e-2 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-2 | 1.53e-4 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-3 | 5.21e-4 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-4 | 1.84e-5 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-5 | 8.05e-7 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-2 | 2.16e-2 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-3 | 2.87e-2 |
Oligodendrocyte | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 5.00e-2 | 2.25e-2 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 5.00e-2 | 4.58e-3 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-2 | 1.89e-2 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-3 | 4.01e-3 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-4 | 3.32e-5 |
Macrophage | BMI by age | BMI at 3 months old | ETC | Helgeland O | 2019 | NA | 7,970 | 1.00e-3 | 4.30e-2 |
Macrophage | BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 1.00e-3 | 2.87e-2 |
Oligodendrocyte | BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 1.00e-2 | 3.85e-2 |
Macrophage | BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 1.00e-3 | 3.58e-2 |
Macrophage | Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-2 | 3.01e-2 |
Macrophage | Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-3 | 7.84e-4 |
Smooth muscle cell | Left ventricular | Left ventricular mass | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-2 | 7.60e-3 |
Oligodendrocyte | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 3.14e-2 |
Oligodendrocyte | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-2 | 4.38e-2 |
Oligodendrocyte | Optic disc area | Optic disc area | ETC | Bonnemaijer PWM | 2019 | NA | 24,509 | 5.00e-2 | 2.07e-2 |
Astrocyte | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-2 | 1.04e-2 |
Astrocyte | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 3.21e-2 |
Smooth muscle cell | Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-2 | 1.46e-2 |
Smooth muscle cell | Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-3 | 3.35e-2 |
Smooth muscle cell | Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-4 | 2.25e-2 |
Oligodendrocyte | Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-4 | 2.25e-2 |
Oligodendrocyte | Temporale grey matter volume | Right planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,039 | 5.00e-2 | 2.99e-2 |
Astrocyte | Temporale asymmetry | Planum temporale asymmetry index | ETC | Carrion-Castillo A | 2020 | NA | 18,049 | 5.00e-2 | 1.90e-2 |
Oligodendrocyte | Temporale grey matter volume | Left planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,037 | 5.00e-2 | 1.73e-3 |
Oligodendrocyte | Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-2 | 2.87e-3 |
Oligodendrocyte | Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-4 | 4.12e-3 |
Oligodendrocyte | Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-5 | 4.07e-2 |
Macrophage | Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-5 | 1.05e-2 |
Oligodendrocyte | Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-4 | 7.23e-3 |
Macrophage | Heart failure | Heart failure | ETC | Shah S | 2020 | 47,309 | 930,014 | 5.00e-2 | 2.14e-2 |
Astrocyte | Heart failure | Heart failure | ETC | Shah S | 2020 | 47,309 | 930,014 | 5.00e-2 | 2.89e-2 |
Oligodendrocyte | Heart failure | Heart failure | ETC | Shah S | 2020 | 47,309 | 930,014 | 1.00e-5 | 1.58e-2 |
Smooth muscle cell | CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.90e-2 |
Smooth muscle cell | CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 3.57e-2 |
Astrocyte | C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.39e-2 |
Smooth muscle cell | C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 3.15e-2 |
Oligodendrocyte | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.27e-3 |
Oligodendrocyte | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 6.34e-3 |
Oligodendrocyte | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.40e-2 |
Macrophage | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.82e-2 |
Macrophage | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 5.63e-3 |
Macrophage | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 2.10e-2 |
Macrophage | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 3.40e-2 |
Oligodendrocyte | CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.81e-2 |
Smooth muscle cell | CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.44e-2 |
Smooth muscle cell | CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.45e-2 |
Oligodendrocyte | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.21e-3 |
Oligodendrocyte | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.86e-2 |
Astrocyte | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 8.91e-4 |
Smooth muscle cell | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 3.57e-2 |
Smooth muscle cell | Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 3.36e-2 |
Oligodendrocyte | Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.62e-2 |
Oligodendrocyte | Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.40e-2 |
Smooth muscle cell | Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 3.57e-2 |
Smooth muscle cell | IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.95e-2 |
Smooth muscle cell | IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.59e-2 |
Oligodendrocyte | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.61e-2 |
Smooth muscle cell | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.52e-2 |
Oligodendrocyte | E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.89e-2 |
Oligodendrocyte | E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.86e-2 |
Smooth muscle cell | E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.59e-2 |
Oligodendrocyte | Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 3.60e-2 |
Smooth muscle cell | Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 3.36e-2 |
Macrophage | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-2 | 1.98e-2 |
Macrophage | Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 5.00e-2 | 1.26e-2 |
Macrophage | Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 1.00e-3 | 3.21e-3 |
Macrophage | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 2.61e-3 |
Macrophage | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 1.87e-3 |
Smooth muscle cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 2.04e-2 |
Smooth muscle cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 1.25e-2 |
Smooth muscle cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 4.60e-2 |
Smooth muscle cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 1.32e-2 |
Smooth muscle cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-5 | 5.01e-4 |
Astrocyte | Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-3 | 4.09e-2 |
Astrocyte | Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-5 | 3.14e-2 |
Astrocyte | Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-3 | 1.99e-3 |
Astrocyte | Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-4 | 1.32e-2 |
Astrocyte | Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-5 | 3.12e-2 |
Astrocyte | Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 5.00e-2 | 9.15e-3 |
Astrocyte | Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-2 | 2.89e-2 |
Astrocyte | Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-4 | 4.91e-2 |
Macrophage | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-3 | 2.41e-2 |
Macrophage | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-4 | 1.46e-2 |
Smooth muscle cell | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-5 | 2.15e-2 |
Oligodendrocyte | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 5.00e-2 | 3.17e-2 |
Astrocyte | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 5.00e-2 | 3.93e-3 |
Smooth muscle cell | COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 5.00e-2 | 2.26e-2 |
Oligodendrocyte | COVID-19 | Severe COVID-19 infection with respiratory failure (analysis I) | ETC | Ellinghaus D | 2020 | 1610 | 2205 | 5.00e-2 | 4.13e-2 |
Oligodendrocyte | COVID-19 | Severe COVID-19 infection with respiratory failure (analysis I) | ETC | Ellinghaus D | 2020 | 1610 | 2205 | 1.00e-2 | 4.40e-2 |
Oligodendrocyte | COVID-19 | Severe COVID-19 infection with respiratory failure (analysis II) | ETC | Ellinghaus D | 2020 | 1610 | 2180 | 5.00e-2 | 2.73e-2 |
Macrophage | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 5.00e-2 | 1.99e-3 |
Macrophage | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-2 | 3.38e-3 |
Macrophage | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-3 | 1.58e-3 |
Macrophage | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-4 | 6.32e-4 |
Macrophage | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-5 | 4.68e-4 |
Smooth muscle cell | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-5 | 7.09e-3 |
Oligodendrocyte | COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 5.00e-2 | 1.65e-3 |
Oligodendrocyte | COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 1.00e-2 | 1.05e-2 |
Oligodendrocyte | COVID-19 | COVID-19 UKBB EUR (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 457,959 | 5.00e-2 | 3.68e-2 |
Oligodendrocyte | COVID-19 | COVID-19 UKBB EUR (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 457,959 | 1.00e-2 | 2.77e-2 |
Oligodendrocyte | COVID-19 | COVID-19 UKBB EUR (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 457,959 | 1.00e-3 | 4.78e-2 |
Macrophage | COVID-19 | COVID-19 UKBB EUR (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 457,959 | 5.00e-2 | 3.68e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.